Market Research Reports and Industry Reports

Therapeutic Class Report Overview : Hepatitis C Virus Infection

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.

Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios VX-135 in 2012 for total of $775m, and Abbott in-licensed Enantas ABT-450 for total of ~$310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an all oral IFN-free treatment with at par or better efficacy / compliance, and novel vaccine candidates.
N/A

List Of Tables

N/A

List Of Figures

N/A

United States Cystic Fibrosis (CF) Therapeutics Market Report 2018

In this report, the United States Cystic Fibrosis (CF) Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end

USD 3800View Report

Global Coronary Artery Disease Therapeutics Market Professional Survey Report 2018

This report studies Coronary Artery Disease Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these

USD 3500View Report

Therapeutic Class Report Overview - Future Of GPR Agonist

Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening

USD 1000View Report

Therapeutic Class Report Overview - Japan Biosimilars

200b worth of biologic products is going off patent by 2015 and this value exceeds ~ 500b if we include products that will see their patent expiries by 2021 in

USD 1000View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1000
  • Site Licence    USD 2000
  • Enterprisewide Licence    USD 3000
$ 1000

Reports Details

Published Date : Feb 2013
No. of Pages :31
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 
istanbul escort istanbul escort istanbul escort izmit escort eskisehir escort samsun escort bursa escort ankara escort konya escort adana escort gaziantep escort kayseri escort izmir escort hatay escort

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
maltepe escort kartal escort manavgat escort manavgat side escort konya escort tuzla escort pendik escort maltepe escort maltepe escort porno